By a News Reporter-Staff News Editor at Biotech Week — According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Synageva Biopharma Corp. (Form S-8) was posted on June 26, 2014.
The SIC code for this company is 2836, Biological Products, (No Diagnostic Substances).
There were 4 documents filed with this form. The SEC file number is 0001193125-14-251115.
The contact information for this company is 33 HAYDEN AVE., LEXINGTON MA 02421, (781) 357-9900.
Our editors provided additional information about Form S-8: This form is used for the registration of securities to be offered to an issuer’s employees pursuant to certain plans.
A U.S. Securities and Exchange Commission filing is a formal document or financial statement submitted to the SEC by publicly-traded companies.
For additional information on this SEC filing see: http://www.sec.gov/Archives/edgar/data/911326/0001193125-14-251115-index.html.
Keywords for this news article include: Pharmaceutical Companies, Drugs, Therapy, SEC Filing, Biopharmaceuticals, Biological Products, Synageva Biopharma Corp., (No Diagnostic Substances).
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Synageva Biopharma Corp. Files SEC Form S-8, Securities To Be Offered To Employees in Employee Benefit Plans (Jun. 26, 2014)
By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing
- 1 min Read
- 07.9.2014
A weekly five-point roundup of critical events in fintech, the future of finance and the next wave of banking industry transformation.
Crush spreads, which have been trending, are barometers of soybean supply and demand and a real-time indicator of processor profitability.
Despite munis’ tax advantages, alternatives' higher yields continue to divert investors who may be wary of interestrate risks.
A weekly five-point roundup of critical events in the energy transition and the implications of climate change for business and finance.
Why have three of the most successful men in Silicon Valley decided to branch out from computing and into nuclear energy?
The Fed model compares the return profile of stocks and US government bonds.
